Tranexamic acid quantification in human whole blood using liquid samples or volumetric absorptive microsampling devices
Lamy et al.
The finding, in our words
The authors developed and validated high-sensitivity LC-MS/MS methods for tranexamic acid quantification in human whole blood, using either liquid samples or dried samples on volumetric absorptive microsampling devices. The methods performed excellently across clinically relevant concentrations, showed stability for up to one month at +50°C, and were validated with clinical samples, supporting decentralised therapeutic drug monitoring of this antifibrinolytic.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
Capillary blood collected with the Mitra® device showed correlation with venous samples for paclitaxel therapeutic drug monitoring, but wide confidence intervals suggest the methods may not be interchangeable. While plasma and whole blood concentrations were more closely aligned, the variability raises questions about using self-collected capillary samples for dose individualisation without further validation.
The validated LC-MS/MS method showed similar pharmacokinetic profiles for albendazole and its metabolites across plasma, whole blood, dried blood spots and Mitra microsamples from hookworm-infected adolescents, supporting microsampling for paediatric pharmacokinetic studies. Mitra extraction proved more robust than dried blood spots during validation and is recommended for future albendazole pharmacokinetic work, despite higher albendazole sulfone concentrations observed in both microsampling devices compared with wet matrices.
Schulz et al., Antimicrobial agents and chemotherapy (paywalled) · source ↗
In lung and renal transplant recipients, VAMS sampling with LC-MS/MS quantification of mycophenolic acid and tacrolimus showed good linearity and accuracy, and with a haematocrit-adjusted conversion formula achieved clinical agreement in most samples; tacrolimus did not require haematocrit correction. The approach is virtually painless and enables richer sampling for more accurate drug exposure estimates, supporting decentralised therapeutic drug monitoring.
Juan et al., Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · source ↗
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.
Huhn & Scherf-Clavel, Therapeutic drug monitoring (paywalled) · source ↗
An LC-MS/MS method for tamoxifen and six metabolites in VAMS was developed and validated, with water prerinsing improving recoveries and poor room temperature stability but stability for at least 100 days at minus 80 degrees Celsius. Plasma to blood ratios were used to estimate plasma equivalent concentrations, and paired VAMS and plasma samples from ten breast cancer patients showed strong correlations and good agreement on Bland-Altman analysis, supporting reliable decentralised TDM.
Kuo et al., Analytical and bioanalytical chemistry (paywalled) · source ↗